11 beta-HSD Inhibitor Market: Competitive Landscape, Pipeline, and Market Analysis 2023

11 beta-HSD Inhibitor are pharmaceutical agents that target the enzyme 11β-hydroxysteroid dehydrogenase, which plays a crucial role in the metabolism of glucocorticoids. By inhibiting this enzyme, these inhibitors have the potential to modulate the local tissue concentrations of glucocorticoids, thereby providing therapeutic benefits in various disease indications. These inhibitors are primarily used in metabolic disorders such as type 2 diabetes and obesity, where dysregulation of glucocorticoid metabolism contributes to disease pathogenesis. They are also being explored for inflammatory and immune-mediated diseases like rheumatoid arthritis and asthma, as well as in the field of oncology to potentially affect tumor growth and the tumor microenvironment. According to WHO, type 2 diabetes affects approximately 422 million people worldwide, and the prevalence is rising. In Europe, the estimated prevalence of type 2 diabetes among adults aged 20-79 is around 8.8%. In the United States, diabetes affects over 34 million people, with around 90-95% of cases being type 2 diabetes. Obesity, a major risk factor for type 2 diabetes, is also on the rise. According to the CDC, in the United States, obesity affects approximately 42.4% of adults. Inflammatory diseases, such as rheumatoid arthritis, affect a significant portion of the population. In Europe, an estimated 0.5-1% of adults have rheumatoid arthritis, while in the United States, it affects around 1.3 million people. Asthma is another prevalent condition, with the global prevalence estimated to be around 339 million people.

The growth drivers of the 11β-HSD inhibitor market include increasing awareness about the role of glucocorticoids in disease pathogenesis, demand for innovative therapeutic options, favorable regulatory policies, advancements in drug delivery technologies, and a strong pipeline of 11β-HSD inhibitors. Companies such as HRA Pharma, AstraZeneca, AbbVie, Actinogen Medical, Boehringer Ingelheim, BMS, Roche, Pfizer, Incyte, Astellas, BMS, and Amgen are pharmaceutical companies operating in the healthcare industry. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, AstraZeneca is currently conducting a clinical trial of the drug AZD4017 for the treatment of diabetes mellitus.

Key Developments

• In Dec 2022, US FDA approved the IND application for the phase IIb trial of Actinogen Medical’s UE-2343 in Alzheimer's disease (Early-stage disease)
• In Feb 2019, AstraZeneca completed a phase-II trial of AZD-4017 in Cushing's syndrome (In volunteers, Combination therapy) in the United Kingdom

Approved 11β-HSD Inhibitor molecules

• Metopirone (metyrapone)
• Xanamem (UE2343)

11β-HSD Inhibitor Pipeline Molecules

• AZD4017
• BI-187004
• BI135585
• BMS-823778
• RG4929
• AZD8329
• HSD-016
• INCB-13739
• ASP3662
• BMS-770767
• AMG 221
• BMS-816336
• P 2202
• RG7234           

Clinical Activity and Development of 11β-HSD Inhibitor

In the 11β-HSD Inhibitor space, there are very few companies, conducting more than more than 50 clinical trials in this category of drugs. For instance,

• In March 2023, Actinogen released pooled adverse events and efficacy data from a clinical trial of Xanamem in Alzheimer's disease
• In April 2020, HRA Pharma completed phase-III clinical trials of Metyrapone in Cushing syndrome in Romania